IGF-1 LR3 research: what the studies have looked at

This page summarises the published research on IGF-1 LR3, for reference. It states what each study investigated and in what model, not an effect to expect, and it is not medical advice. IGF-1 LR3 is a laboratory reagent and has not been tested as a medicine in humans; what we supply is a research chemical for laboratory use only.

What IGF-1 LR3 is

IGF-1 LR3 (Long R3 IGF-1) is a recombinant analogue of insulin-like growth factor 1, engineered with an extended N-terminus and a substitution that lowers its binding to IGF-binding proteins, so it stays active longer in cell culture. It is used as a research reagent, commonly to support cell growth in culture; it has not been developed or tested as a human medicine.

What the studies investigated

Sundgren et al. (2003), American Journal of Physiology 285(6):R1481. Fetal sheep cardiomyocytes. Investigated cell proliferation and ERK/PI3K-dependent signalling Source.

Steeb et al. (1995), Gut 37(5):630. Rat, infusion. Investigated effects on intestinal growth Source.

Grimes and Hammond (1992), Endocrinology 131(2):553. Granulosa cells. Investigated its low affinity for IGF-binding proteins Source.

Mechanism, as described in the literature

The literature describes IGF-1 LR3 as an IGF-1 analogue that signals through the IGF-1 receptor while binding poorly to IGF-binding proteins, which is reported to make it more available to cells in culture. The cited work is in isolated cells and in animals; it is a reagent-grade tool, not a study of a treatment in people.

The material we supply

We supply IGF-1 LR3 as a research chemical, released against a written specification with a batch certificate of analysis. It is not a medicine and is not for human or animal use. For the vial sizes, the price per mg and how to order, see the IGF-1 LR3 compound page; the COA lookup pulls the certificate for any batch. The references above link to each study’s record; this summary is for research and educational reference only.